According to research published on April 30, 2026, in Hepatobiliary & Pancreatic Diseases International, a new composite scoring system called the Seven Up score can spare more than 30% of liver transplant recipients from unnecessary high-dose steroid treatment for early rejection. Led by Prof. Jan P. Lerut at the Université catholique de Louvain in Brussels, Belgium, the study analyzed 421 adult transplant patients and found that while 37.3% showed moderate to severe T cell-mediated rejection on day seven biopsies, only 4.5% actually required medical intervention.
The Shift From Biopsy-Only Monitoring to Bio-Histological Evaluation
For decades, the standard approach in transplant hepatology relied entirely on the Banff histology system, using biopsy findings alone to guide treatment decisions. According to published data, the Banff system grades portal inflammation on a scale of 0 to 9. Traditionally, any patient scoring between 6 and 9 received immediate high-dose steroid treatment. However, clinicians have long noted that this aggressive practice exposes 10% to 40% of recipients to severe complications, including infections, cardiovascular events, kidney dysfunction, and metabolic disorders.
The newly developed Seven Up score changes this dynamic by combining routine day seven biopsy findings with simple blood test trends. The model pairs the traditional Banff score (0–9) with a secondary metric called the Bio-score (0–4). Data published in Hepatobiliary & Pancreatic Diseases International show that the Bio-score evaluates shifts in three routine blood parameters between post-operative days five and seven: increasing total bilirubin levels, an elevated eosinophil count where absolute eosinophils are 600 per microliter or higher, and a drop in platelets.
Did you know?
Under traditional biopsy-only protocols, all 157 patients in the study who scored between 6 and 9 on the Banff scale would have received immediate steroid therapy. Applying the Seven Up score restricted treatment to just 19 patients, safely sparing 138 individuals from unnecessary pharmaceutical toxicity.
Validating the Bio-Score and Protecting Long-Term Outcomes
When researchers evaluated the long-term impacts of withholding treatment from patients with high Banff scores but low Bio-scores, they found that long-term graft and patient survival rates remained comparable between the treated and untreated groups. Furthermore, the Bio-score proved to be highly accurate in diagnosing very early clinically relevant T cell-mediated rejection, producing an area under the curve of 0.78, a 95% confidence interval spanning from 0.68 to 0.89, and a P value of less than 0.001.
As the study authors stated in published reports, “The key message is simple: not every rejection seen under the microscope needs to be treated. For decades, we’ve been treating the biopsy rather than the patient. Our data show that the liver allograft is remarkably resilient—most early histological rejection resolves without intervention.” By establishing a threshold of a Banff score of 6 or higher alongside a Bio-score of 2 or greater to classify rejection as clinically relevant, medical professionals can successfully safeguard patients from avoidable steroid-induced harm without hindering their recovery.
Frequently Asked Questions
What is the Seven Up score?
The Seven Up score is a diagnostic model that combines day seven Banff biopsy findings with a four-point Bio-score based on routine blood test trends to identify liver transplant patients who genuinely require treatment for early rejection.
How many patients were spared treatment in the study?
According to the research from Université catholique de Louvain, the Seven Up score spared 138 patients—amounting to 32.8% of the study group—from unnecessary early steroid treatment during the first 15 days post-transplant.
Which blood markers are used in the Bio-score?
The Bio-score tracks changes between post-operative day five and day seven in three specific markers: rising total bilirubin, rising eosinophil count, and declining platelet count.
Explore More: Want to stay updated on the latest breakthroughs in transplant medicine and clinical research? Subscribe to our newsletter or explore our archives for more in-depth reporting.
Keep reading